Until today, no medication is approved for the treatment of this disease
products often lack quality control, raising fears of contamination, incorrect dosing, or dangerous ingredients, with the FDA warning against compounding it due to insufficient safety data
Results The disruption of D2R-DAT stimulates locomotor activity As aforementioned, we developed an interfering peptide (TAT-DAT NT ) to disrupt the interaction between DAT and D2R, which can increase locomotor activity in mice [25]
Indeed, it has to be considered that oral hyaluronic acid supplementation, which could further improve the compliance of treatment, has to be evaluated in terms of bioavailability and absorption considering that the size of the molecule and its breakdown during digestion which could affect its therapeutic potential [53,54]
However, the most significant difference is between systemic circulation (minutes) and topical application on the skin (hours of local residence time)
